Triple-negative breast cancer molecular subtypes and potential detection targets for biological therapy indications
Carcinogenesis · 2025
DOI: 10.1093/carcin/bgaf006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Carcinogenesis, 2025. Verfasst von Yanchuan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and W…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Biomarkers, Tumor, Molecular Targeted Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 148 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sichuan Science and Technology Program, Foundation of Xinglin Scholar Research Program Project of Chengdu University.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer associated with poor prognosis. While chemotherapy remains the conventional treatment approach, its efficacy is limited and often accompanied by significant toxicity. Advances in precision-targeted therapies have expanded treatment options for TNBC, including immunotherapy, poly (ADP-ribose) polymerase inhibitors, androgen receptor inhibitors, cell cycle-dependent kinase inhibitors, and signaling pathway inhibitors. However, the heterogeneous nature of TNBC contributes to variations in treatment outcomes, underscoring the importance of identifying intrinsic molecular subtypes for personalized therapy. Additionally, due to patient-specific variability, the therapeutic response to targeted treatments is inconsistent. This highlights the need to strategize patients based on potential therapeutic targets for targeted drugs to optimize treatment strategies. This review summarizes the classification strategies and immunohistochemical (IHC) biomarkers for TNBC subtypes, along with potential targets for identifying indications for targeted drug therapy. These insights aim to support the development of personalized treatment approaches for TNBC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chengdu, China.
- Sichuan Key Laboratory of Medical Molecular Testing, College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, Institute of Breast Health Medicine, West China Hospital, Sichuan University, Chengdu, P.R. China.
- Department of Clinical Laboratory, Chengdu Fifth People's Hospital, Chengdu, China.
ORCID-Profile: Yingshuang Wang
Förderung
- National Natural Science Foundation of China
- Sichuan Science and Technology Program
- Foundation of Xinglin Scholar Research Program Project of Chengdu University
Zitieren
APA
Zhang, Y., Li, Q., Lan, J., Xie, G., Zhang, G., Cui, J., Leng, P., & Wang, Y. (2025). Triple-negative breast cancer molecular subtypes and potential detection targets for biological therapy indications. Carcinogenesis. https://doi.org/10.1093/carcin/bgaf006
Vancouver
Zhang Y, Li Q, Lan J, Xie G, Zhang G, Cui J, et al. Triple-negative breast cancer molecular subtypes and potential detection targets for biological therapy indications. Carcinogenesis. 2025. doi:10.1093/carcin/bgaf006
BibTeX
@article{Zhang2025,
author = {Zhang, Yanchuan and Li, Qinghua and Lan, Jie and Xie, Guojing and Zhang, Guangjie and Cui, Junhao and Leng, Ping and Wang, Yingshuang},
title = {Triple-negative breast cancer molecular subtypes and potential detection targets for biological therapy indications},
journal = {Carcinogenesis},
year = {2025},
doi = {10.1093/carcin/bgaf006}
}
EUVIMED